Claims for Patent: 9,308,276

Summary for Patent: 9,308,276

Title:	Combination therapy for treatment of cancer
Abstract:	The present invention relates to methods and compositions for the treatment of cancer. Some embodiments include methods of treating cancer comprising administering a chemotherapeutic agent associated with albumin, administering a second chemotherapeutic agent; and administering a third chemotherapeutic agent.
Inventor(s):	Khong; Hung T. (Mobile, AL)
Assignee:	UNIVERSITY OF SOUTH ALABAMA (Mobile, AL)
Application Number:	14/117,832
Patent Claims:	1. A method of treating a HER2 negative breast cancer in a subject in need thereof comprising: administering a chemotherapeutic agent associated with or bound to albumin, wherein the chemotherapeutic agent associated with or bound to albumin is selected from the group consisting of paclitaxel, docetaxel, and rapamycin; administering a topoisomerase inhibitor; and administering an alkylating agent, wherein the chemotherapeutic agent associated with or bound to albumin, the topoisomerase inhibitor, and the alkylating agent are administered on the same day. 2. The method of claim 1, wherein administration of the chemotherapeutic agent associated with or bound to albumin is repeated. 3. The method of claim 1, wherein administration of the topoisomerase inhibitor and the agent is not repeated. 4. The method of claim 1, wherein the chemotherapeutic agent associated with or bound to albumin comprises nab-paclitaxel. 5. The method of claim 4, wherein the administered dose of nab-paclitaxel is between about 50 mg/m.sup.2 and about 200 mg/m.sup.2. 6. The method of claim 4, wherein the administered dose of nab-paclitaxel is selected from the group consisting of 100 mg/m.sup.2 and 150 mg/m.sup.2. 7. The method of claim 1, wherein the topoisomerase inhibitor is doxorubicin. 8. The method of claim 1, wherein the alkylating agent is cyclophosphamide. 9. The method of claim 1, wherein the chemotherapeutic agent associated with or bound to albumin is administered on days 1 and 8. 10. The method of claim 2, wherein the chemotherapeutic agent associated with or bound to albumin is administered at an interval of at least about 5 days. 11. The method of claim 2, wherein the administration of the chemotherapeutic agent associated with or bound to albumin is repeated at least 2 times. 12. The method of claim 2, wherein the administration of the chemotherapeutic agent associated with or bound to albumin is repeated at least 5 times. 13. The method of claim 3, wherein administration of the chemotherapeutic agent associated with or bound to albumin is repeated. 14. The method of claim 13, wherein administration of the chemotherapeutic agent associated with or bound to albumin is repeated at least 2 times. 15. The method of claim 13, wherein administration of the chemotherapeutic agent associated with or bound to albumin is repeated at least 5 times. 16. The method of claim 13, wherein administration of the chemotherapeutic agent associated with or bound to albumin comprises is repeated with an interval of at least about 5 days. 17. The method of claim 4, wherein at least about 100 mg/m.sup.2 nab-paclitaxel is administered on days 1 and 8, at least about 50 mg/m.sup.2 doxorubicin is administered on day 1, and at least about 500 mg/m.sup.2 cyclophosphamide is administered on day 1. 18. The method of claim 17, further comprising administering pegfilgrastim on day 9. 19. The method of claim 1, wherein the breast cancer is triple negative breast cancer. 20. The method of claim 1, wherein the chemotherapeutic agent associated with or bound to albumin is nab-paclitaxel, the topoisomerase inhibitor is doxorubicin, and the alkylating agent is cyclophosphamide. 21. The method of claim 1, wherein the alkylating agent is selected from the group consisting of mechlorethamine, cyclophosphamide, ifosfamide, trofosfamide, chlorambucil, melphalan, prednimustine, bendamustine, uramustine, carmustine, lomustine, fotemustine, nimustine, ranimustine, streptozocin, busulfan, mannosulfan, treosulfan, carboquone, N,N'N'-triethylenethiophosphoramide (thioTEPA), triaziquone, and triethylenemelamine. 22. The method of claim 1, wherein the topoisomerase inhibitor is selected from the group consisting of camptothecin, topotecan, irinotecan, rubitecan, belotecan, etoposide, teniposide, aclarubicin, daunorubicin, doxorubicin, epirubicin, idarubicin, amrubicin, pirarubicin, valrubicin, zorubicin, mitoxantrone, and pixantrone.

Details for Patent 9,308,276

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Amgen, Inc.	NEULASTA	pegfilgrastim	Injection	125031	01/31/2002		2031-05-17
Amgen, Inc.	NEULASTA ONPRO	pegfilgrastim	Injection	125031	12/23/2014		2031-05-17